Inventor · disambiguated record
Christophe Blanchetot
Also filed as: BLANCHETOT CHRISTOPHE · BLANCHETOT CHRISTOPHE FREDERIC JEROME
34 granted patents·28 pending applications·133 citations·filing 2007–2025
96Inventor score
Top patents by PatentIndex Score
62 records- 0193US9315576B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted Apr 19, 2016·5 cites·12 claims
- 0293US8524231B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2011·Granted Sep 3, 2013·19 cites·32 claims
- 0393US8444976B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2009·Granted May 21, 2013·12 cites·19 claims
- 0492US11505585B2FcRn antagonists and methods of useargenx BV·Filed 2017·Granted Nov 22, 2022·7 cites·10 claims
- 0592US10316073B2FCRN antagonists and methods of useARGENX BVBA·Filed 2014·Granted Jun 11, 2019·20 cites·10 claims
- 0692US9221918B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted Dec 29, 2015·5 cites·4 claims
- 0791US9346891B2Antigen binding polypeptidesARGEN X BV·Filed 2015·Granted May 24, 2016·5 cites·20 claims
- 0890US12344678B2FcRn/HSA binding molecules and methods of useargenx BV·Filed 2024·Granted Jul 1, 2025·3 cites·14 claims
- 0990US9428580B2Antigen binding polypeptidesDREIER TORSTEN·Filed 2011·Granted Aug 30, 2016·5 cites·28 claims
- 1089US11161900B2Antibodies that specifically bind to human complement factor C2bARGENX BVBA·Filed 2019·Granted Nov 2, 2021·2 cites·12 claims
- 1189US9005963B2Amino acid sequences directed against cellular receptors for viruses and bacteriaBLANCHETOT CHRISTOPHE·Filed 2009·Granted Apr 14, 2015·13 cites·18 claims
- 1289US8906680B2Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disordersBLANCHETOT CHRISTOPHE·Filed 2007·Granted Dec 9, 2014·11 cites·34 claims
- 1385US9926364B2Chimeric human-llama antigens and methods of useARGEN X N V·Filed 2012·Granted Mar 27, 2018·5 cites·18 claims
- 1482US9156914B2Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disordersBLANCHETOT CHRISTOPHE·Filed 2007·Granted Oct 13, 2015·4 cites·10 claims
- 1581US2024002484A1ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USEargenx BV·Filed 2023·Application pending·0 cites
- 1681US2024158492A1Il-6 binding moleculesargenx BV·Filed 2023·Application pending·0 cites
- 1780US9803018B2Amino acid sequences directed against cellular receptors for viruses and bacteriaABLYNX NV·Filed 2015·Granted Oct 31, 2017·2 cites·14 claims
- 1880US9212226B2Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the sameBLANCHETOT CHRISTOPHE·Filed 2009·Granted Dec 15, 2015·5 cites·12 claims
- 1979US11708403B2Antibodies to human complement factor C2B and methods of useargenx BV·Filed 2022·Granted Jul 25, 2023·0 cites·14 claims
- 2079US10696741B2Anti-IL-22R antibodiesARGENX BVBA·Filed 2019·Granted Jun 30, 2020·1 cites·23 claims
- 2179US10040870B2Highly diverse combinatorial antibody librariesARGENX BVBA·Filed 2013·Granted Aug 7, 2018·5 cites·4 claims
- 2278US11591386B2Antibodies to human complement C2Bargenx BV·Filed 2021·Granted Feb 28, 2023·0 cites·20 claims
- 2376US2025388700A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 2476US2025388699A1Variant fc regionsargenx BV·Filed 2025·Application pending·0 cites
- 2575US11827701B2IL-6 binding moleculesargenx BV·Filed 2021·Granted Nov 28, 2023·0 cites·18 claims
- 2675US10183995B2IL-6 binding moleculesARGEN X N V·Filed 2013·Granted Jan 22, 2019·2 cites·36 claims
- 2775US2024368311A1Bispecific antigen binding constructargenx BV·Filed 2024·Application pending·0 cites
- 2875US2023088269A1Anti-il-22r antibodiesARGENX BVBA·Filed 2022·Application pending·0 cites
- 2975US2025059262A1Method of preparing ph-dependent antibodiesargenx BV·Filed 2024·Application pending·0 cites
- 3072US11117959B2IL-6 binding moleculesARGENX BVBA·Filed 2019·Granted Sep 14, 2021·0 cites·15 claims
- 3172US10487156B2Asymmetric multispecific antibodiesARGENX BVBA·Filed 2015·Granted Nov 26, 2019·1 cites·6 claims
- 3271US11066473B2Galectin-10 antibodiesARGENX IIP BV·Filed 2019·Granted Jul 20, 2021·1 cites·24 claims
- 3371US2024026010A1Galectin-10 antibodiesargenx BV·Filed 2023·Application pending·0 cites
- 3471US2025382388A1Fcrn/hsa binding molecules and methods of useargenx BV·Filed 2025·Application pending·0 cites
- 3570US2025122288A1Fcrn binding molecules and methods of useargenx BV·Filed 2024·Application pending·0 cites
- 3670US2022275035A1Fcrn antagonists and methods of useargenx BV·Filed 2022·Application pending·0 cites
- 3769US11447544B2Anti-IL-22R antibodiesargenx BV·Filed 2019·Granted Sep 20, 2022·0 cites·26 claims
- 3869US11261246B2Anti-IL-22R antibodiesARGENX BVBA·Filed 2019·Granted Mar 1, 2022·0 cites·23 claims
- 3968US2024352138A1Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13rargenx BV·Filed 2024·Application pending·0 cites
- 4066US11492401B2Therapeutic musk antibodiesUNIV NEW YORK·Filed 2021·Granted Nov 8, 2022·0 cites·24 claims
- 4163US11649295B2Asymmetric multispecific antibodiesargenx BV·Filed 2019·Granted May 16, 2023·0 cites·16 claims
- 4263US2024034779A1Antibodies targeting complement factor d and uses therofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 4363US2016319040A1Antigen binding polypeptidesARGEN-X B V·Filed 2016·Application pending·0 cites
- 4461US12071486B2Bispecific antigen binding constructargenx BV·Filed 2018·Granted Aug 27, 2024·0 cites·4 claims
- 4561US2024409645A1Binding Molecules Targeting IL-2 ReceptorDUALYX NV·Filed 2022·Application pending·0 cites
- 4659US11713354B2Galectin-10 antibodiesARGENX IIP BV·Filed 2021·Granted Aug 1, 2023·0 cites·15 claims
- 4758US2024109960A1Anti-il-9 antibodies and methods of use thereofargenx BV·Filed 2023·Application pending·0 cites
- 4857US2025313611A1Sarbecovirus spike s2 subunit bindersVIB VZW·Filed 2023·Application pending·0 cites
- 4956US12060413B2Method of preparing pH-dependent antibodiesargenx BV·Filed 2018·Granted Aug 13, 2024·0 cites·33 claims
- 5056US2023151091A1Therapeutic musk antibodiesARGENX IIP BV·Filed 2022·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →